| scholarly article | Q13442814 |
| P50 | author | Marcel Kool | Q90637389 |
| P2093 | author name string | Michael D Taylor | |
| Vijay Ramaswamy | |||
| Sung-Hye Park | |||
| Ji Hoon Phi | |||
| Seung-Ki Kim | |||
| Ji Yeoun Lee | |||
| Seung Ah Choi | |||
| Ae Kyung Park | |||
| Heesun Cheong | |||
| Florence Cavalli | |||
| P2860 | cites work | Medulloblastoma molecular dissection: the way toward targeted therapy | Q38146509 |
| Targeting forkhead box transcription factors FOXM1 and FOXO in leukemia (Review). | Q38245075 | ||
| Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study. | Q38374250 | ||
| Intertumoral Heterogeneity within Medulloblastoma Subgroups | Q38671456 | ||
| Polo-like Kinase-1 Regulates Myc Stabilization and Activates a Feedforward Circuit Promoting Tumor Cell Survival | Q38738154 | ||
| Treating cancer with selective CDK4/6 inhibitors | Q38794109 | ||
| Over-expression of FoxM1 is associated with adverse prognosis and FLT3-ITD in acute myeloid leukemia | Q39019814 | ||
| Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors | Q39226360 | ||
| Cancer cell metabolism: the essential role of the nonessential amino acid, glutamine. | Q39249420 | ||
| Notch Shapes the Innate Immunophenotype in Breast Cancer | Q42513427 | ||
| Mitochondrial one-carbon metabolism maintains redox balance during hypoxia | Q43058117 | ||
| The whole-genome landscape of medulloblastoma subtypes | Q46567834 | ||
| Anti-Jagged Immunotherapy Inhibits MDSCs and Overcomes Tumor-Induced Tolerance. | Q47807019 | ||
| Jagged1 promotes aromatase inhibitor resistance by modulating tumor-associated macrophage differentiation in breast cancer patients | Q48090571 | ||
| Targeting polo-like kinase 1 for cancer therapy. | Q53348000 | ||
| Inhibition of Glycolysis and Glutaminolysis: Emerging Drug Discovery Approach to Combat Cancer. | Q54978523 | ||
| Signaling Pathways Regulating Redox Balance in Cancer Metabolism. | Q54979494 | ||
| Notch Signaling in the Tumor Microenvironment | Q57293760 | ||
| A clinical study assessing the tolerability and biological effects of infliximab, a TNF-α inhibitor, in patients with advanced cancer | Q61819218 | ||
| Normal approximation diagnostics for the Cox model | Q73789905 | ||
| FoxM1 dances with mitosis | Q81358769 | ||
| Subtype-specific signaling pathways and genomic aberrations associated with prognosis of glioblastoma | Q90570639 | ||
| Plk1-dependent phosphorylation of FoxM1 regulates a transcriptional programme required for mitotic progression | Q24319945 | ||
| Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles | Q24536351 | ||
| Molecular subgroups of medulloblastoma: the current consensus | Q24615271 | ||
| Fundamentals of cancer metabolism | Q26744062 | ||
| Lipid metabolic reprogramming in cancer cells | Q26774859 | ||
| Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy | Q26991736 | ||
| Novel therapeutic targets of tumor metabolism | Q27005930 | ||
| Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials | Q27852946 | ||
| Exploration, normalization, and summaries of high density oligonucleotide array probe level data | Q27861098 | ||
| FOXM1 is a downstream target of Gli1 in basal cell carcinomas | Q28218367 | ||
| Sonic Hedgehog-dependent proliferation in a series of patients with colorectal cancer | Q28240244 | ||
| Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling | Q28296761 | ||
| Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors | Q33252671 | ||
| Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas | Q33410380 | ||
| FoxM1 is a general target for proteasome inhibitors | Q33492774 | ||
| Anti-Inflammatory Agents for Cancer Therapy | Q33744129 | ||
| Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas | Q34167499 | ||
| Regorafenib for cancer | Q34274239 | ||
| TLN-4601 suppresses growth and induces apoptosis of pancreatic carcinoma cells through inhibition of Ras-ERK MAPK signaling | Q34344787 | ||
| Molecular subgroups of medulloblastoma | Q35101347 | ||
| Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling | Q35748649 | ||
| FOXM1 and polo-like kinase 1 are co-ordinately overexpressed in patients with gastric adenocarcinomas | Q35843942 | ||
| Phase I trial of weekly MK-0752 in children with refractory central nervous system malignancies: a pediatric brain tumor consortium study | Q36378403 | ||
| The FOXM1-PLK1 axis is commonly upregulated in oesophageal adenocarcinoma. | Q36385649 | ||
| The Emerging Hallmarks of Cancer Metabolism | Q36468964 | ||
| FOXM1 participates in PLK1-regulated cell cycle progression in renal cell cancer cells | Q36741118 | ||
| Risk stratification of childhood medulloblastoma in the molecular era: the current consensus | Q36901551 | ||
| Medulloblastoma comprises four distinct molecular variants | Q36920479 | ||
| Signaling pathway and molecular subgroups of medulloblastoma | Q36956174 | ||
| The rationale for targeted therapies in medulloblastoma | Q37409736 | ||
| Medulloblastomics: the end of the beginning | Q37469904 | ||
| The roles of FOXM1 in pancreatic stem cells and carcinogenesis | Q37583296 | ||
| Cytogenetic prognostication within medulloblastoma subgroups | Q37627692 | ||
| Milatuzumab - a promising new immunotherapeutic agent. | Q37646791 | ||
| Targeting Polo-like kinase in cancer therapy | Q37672825 | ||
| FOXM1: From cancer initiation to progression and treatment. | Q37943070 | ||
| Medulloblastoma stem cells: where development and cancer cross pathways. | Q37995022 | ||
| FOXM1 (Forkhead box M1) in tumorigenesis: overexpression in human cancer, implication in tumorigenesis, oncogenic functions, tumor-suppressive properties, and target of anticancer therapy | Q38122806 | ||
| P433 | issue | 1 | |
| P921 | main subject | metabolic pathway | Q68685 |
| medulloblastoma | Q1333608 | ||
| P304 | page(s) | 571 | |
| P577 | publication date | 2019-06-11 | |
| P1433 | published in | BMC Cancer | Q326300 |
| P1476 | title | Subgroup-specific prognostic signaling and metabolic pathways in pediatric medulloblastoma | |
| P478 | volume | 19 |
| Q93163558 | Arsenic Trioxide exerts cytotoxic and radiosensitizing effects in pediatric Medulloblastoma cell lines of SHH Subgroup | cites work | P2860 |
Search more.